Alpha Cognition Adds Biotech Veteran to Board Amid Commercial Launch Push
Event summary
- Alpha Cognition appointed Bethany Sensenig to its Board of Directors on April 15, 2026.
- Sensenig brings 13 years of experience at Biogen and leadership roles at Radius Health, 9 Meters Biopharma, and Minovia Therapeutics.
- Len Mertz, a founding board member and former Chairman, will not seek re-election.
- Alpha Cognition is preparing for the commercial launch of ZUNVEYL, its FDA-approved Alzheimer’s treatment.
The big picture
Alpha Cognition’s board refresh comes as it transitions from clinical-stage to commercialization, a critical phase for biotech firms. Sensenig’s background in scaling commercial-stage biopharmaceuticals suggests a focus on operational efficiency and market penetration. The departure of a long-serving board member may also indicate a shift toward more commercially oriented governance.
What we're watching
- Commercialization Execution
- How Sensenig’s operational expertise will accelerate ZUNVEYL’s market launch and revenue growth.
- Board Dynamics
- Whether the departure of founding board member Len Mertz signals a strategic pivot or leadership transition.
- Pipeline Progress
- The pace at which Alpha Cognition advances its sublingual and intranasal formulations for Alzheimer’s and mTBI.
Related topics